SRES-285-119
Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S3442; text: CR S3441)
Sponsored by Lindsey Graham (R-SC)
What it does
This resolution designates July 16, 2025, as "Glioblastoma Awareness Day." It is a commemorative resolution only and does not create, modify, or fund any federal program, mandate any action, or carry the force of law. It passed the Senate by unanimous consent.
Who benefits
Patients diagnosed with glioblastoma, a rare and aggressive malignant brain tumor. Family members and caregivers of glioblastoma patients. Advocacy organizations focused on brain cancer research and awareness. Researchers and clinicians working in neuro-oncology, who may benefit from increased public attention to the disease.
Who is hurt
No group is materially harmed by this resolution. It imposes no costs, mandates, or restrictions on any individual, organization, or government entity.
Supporters argue
Supporters argue that glioblastoma is one of the most lethal cancers, with a median survival of roughly 15 months after diagnosis and a five-year survival rate below 10%, yet it receives comparatively limited public awareness relative to other cancers. They contend that designating an awareness day draws national attention to the disease, potentially encouraging research funding, early diagnosis conversations, and support for affected families.
Opponents argue
Opponents argue that commemorative resolutions consume limited congressional floor time without producing measurable policy outcomes — no funding is appropriated, no research is mandated, and no patient care is improved by the designation alone. They contend that if Congress wishes to address glioblastoma, it should direct resources toward NIH research grants or patient support programs rather than symbolic declarations.